General Notices

• Notice of NIAAA Data-Sharing Guidance for Human Subjects Grants Research Funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) [4th Revision]
  (NOT-AA-22-011)
  National Institute on Alcohol Abuse and Alcoholism
  

• Notice of NICHD Participation on PAR-21-358 " Risk and Protective Factors of Family Health and Family Level Interventions (R01 - Clinical Trial Optional)"
  (NOT-HD-22-004)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  

• Notice of Clarification of Research Priorities for RFA-NR-22-002, "Advancing Integrated Models (AIM) of Care to Improve Maternal Health Outcomes among Women Who Experience Persistent Disparities (R01 Clinical Trial Required)"
  (NOT-NR-22-012)
  National Institute of Nursing Research
  

• Notice Announcing FAQs, Webinar Recording, and Presentation for RFA-NR-22-001 "Evaluating the Impact of COVID-19 Pandemic-related Food and Housing Policies and Programs on Health Outcomes in Health Disparity Populations (R01 Clinical Trial Optional)"
  (NOT-NR-22-013)
  National Institute of Nursing Research
  

• The National Institutes of Health (NIH) Sexual & Gender Minority Research Office Request for Nominations for 2022 SGM Research Investigator Awards Program
  (NOT-OD-22-088)
  Office of the Director, NIH
  

• Notice of Pre-Application Webinar and Availability of FAQs for RFA-OD-22-003, Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54 Clinical Trial Not Allowed)
  (NOT-OD-22-089)
  Office of Disease Prevention
  National Institute on Drug Abuse
  

• Notice of Pre-Application Webinar and Availability of FAQs for RFA-OD-22-004, Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54 Clinical Trial Optional)
  (NOT-OD-22-090)
  Office of Disease Prevention
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  

• Technical Assistance Webinar for PAR 22-115 and PAR 22-120: Research on Community Level Interventions for Firearm and Related Violence Injury and Mortality Prevention (CLIF-VP)
  (NOT-OD-22-093)
  Office of Behavioral and Social Sciences Research
  

• Request for Information (RFI) on Capacity and Support Needed to Increase Community-Based Research Networks Participation in Alzheimers Disease and Related Dementias (AD/ADRD) Clinical Trials
  (NOT-AG-22-018)
  National Institute on Aging
  

• NIH Request for Information (RFI) on Interdisciplinary Research Opportunities that Bridge Neuroscience and Environmental Health Science
  (NOT-NS-22-076)
  National Institute of Neurological Disorders and Stroke
  National Center for Complementary and Integrative Health
  National Institute on Aging
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  Office of Behavioral and Social Sciences Research
  Office of Research on Women's Health
  

Notice of Changes to Funding Opportunities

• Notice of Participation of the National Institute on Aging (NIA) in PAR-22-072 "Measures and Methods to Advance Research on Minority Health and Health Disparities-Related Constructs (R01 Clinical Trial Not Allowed)"
  (NOT-AG-22-016)
  National Institute on Aging
  

• Notice of Participation of the National Institute on Aging (NIA) in PAR-20-084 "NIBIB Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)"
  (NOT-AG-22-019)
  National Institute on Aging
  

• Notice of Change to Eligibility Information in PAR-22-075, NIAID Career Transition Award (K22 Independent Clinical Trial Not Allowed)
  (NOT-AI-22-036)
  National Institute of Allergy and Infectious Diseases
  

• Notice of Participation of the National Center for Complementary and Integrative Health (NCCIH) in PAR-21-173, "Support for Research Excellence First Independent Research (SuRE-First) Award (R16 - Clinical Trial Not Allowed)
  (NOT-AT-22-014)
  National Center for Complementary and Integrative Health
  

• Notice of Participation of the National Center for Complementary and Integrative Health (NCCIH) in PAR-21-169, "Support for Research Excellence (SuRE) Award (R16 Clinical Trial Not Allowed)
  (NOT-AT-22-015)
  National Center for Complementary and Integrative Health
  

• Notice of Correction to Letters of Support Expectations for RFA-MH-22-130, "Integrating Mental Health Care into Health Care Systems in Low- and Middle-Income Countries (R01 Clinical Trial Optional)"
  (NOT-MH-22-185)
  National Institute of Mental Health
  

Notices of Intent to Publish

• Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention and Control Clinical Trials Planning Grant Program (R34 Clinical Trials Optional)
  (NOT-CA-22-061)
  National Cancer Institute
  

• Notice of Intent to Publish a Funding Opportunity Announcement for Cancer Prevention and Control Clinical Trials Planning Grant (U34 Clinical Trials Optional)
  (NOT-CA-22-062)
  National Cancer Institute
  

Requests for Proposal

• 2022 NIAID Omnibus Broad Agency Announcement HHS-NIH-NIAID-BAA2022-1 Now Available
  (NOT-AI-22-039)
  National Institute of Allergy and Infectious Diseases
  

Funding Opportunities

• Chronic, Non-Communicable Diseases and Disorders Across the Lifespan: Fogarty International Research Training Award (NCD-LIFESPAN) (D43 Clinical Trial Optional)
  (PAR-22-104)
  John E. Fogarty International Center
  National Center for Complementary and Integrative Health
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Office of Disease Prevention
  Office of Research on Women's Health
  Application Receipt Date(s): Multiple dates, see announcement.
  
  

• Centers of Excellence in Genomic Science (RM1 Clinical Trial Optional)
  (PAR-22-107)
  National Human Genome Research Institute
  National Institute of Mental Health
  Application Receipt Date(s): June 21, 2024
  
  

• International Bioethics Research Training Program (D43 Clinical Trial Optional)
  (PAR-22-116)
  John E. Fogarty International Center
  National Human Genome Research Institute
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): June 06, 2024
  
  

• International Research Ethics Education and Curriculum Development Award (R25 Clinical Trial Not Allowed)
  (PAR-22-118)
  John E. Fogarty International Center
  National Human Genome Research Institute
  National Institute of Allergy and Infectious Diseases
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): June 06, 2024
  
  

• Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
  (PAR-22-123)
  National Institute of Biomedical Imaging and Bioengineering
  National Cancer Institute
  National Eye Institute
  National Institute on Aging
  Application Receipt Date(s): January 07, 2025
  
  

• NIA Program Project Applications (P01 Clinical Trial Optional)
  (PAR-22-130)
  National Institute on Aging
  Application Receipt Date(s): September 07, 2025
  
  

• NEI Regenerative Medicine Clinical Trial Planning Grant (R34 - Clinical Trials Not Allowed)
  (PAR-22-135)
  National Eye Institute
  Application Receipt Date(s): May 07, 2025
  
  

• Emergency Awards: Biocontainment Facility Improvements and Building System Upgrades to Support Pandemic Preparedness (G20 Clinical Trial Not Allowed)
  (RFA-AI-22-019)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): April 19, 2022 All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s). Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. No late applications will be accepted for this Funding Opportunity Announcement.
  
  

• Development of HIV Broadly Neutralizing Antibody Susceptibility Assays (R61/R33 Clinical Trial Not Allowed)
  (RFA-AI-22-022)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): August 03, 2022
  
  

• Cancer Control Research in Persistent Poverty Areas (U54 Clinical Trial Optional)
  (RFA-CA-22-015)
  National Cancer Institute
  Application Receipt Date(s): July 06, 2022
  
  

• CAPSTONE Centers for Multidisciplinary Research in Child Abuse and Neglect (P50) (Clinical Trial Optional)
  (RFA-HD-23-007)
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  Application Receipt Date(s): July 27, 2022
  
  

• Addressing Mental Health Disparities Research Gaps: Aggregating and Mining Existing Data Sets for Secondary Analyses (R01 Clinical Trial Not Allowed)
  (RFA-MH-22-200)
  National Institute of Mental Health
  Application Receipt Date(s): October 18, 2022
  
  

• Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54 Clinical Trial Not Allowed)
  (RFA-OD-22-003)
  Office of Disease Prevention
  National Institute on Drug Abuse
  Application Receipt Date(s): July 14, 2022
  
  

• Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54 Clinical Trial Optional)
  (RFA-OD-22-004)
  Office of Disease Prevention
  National Cancer Institute
  National Heart, Lung, and Blood Institute
  National Institute on Drug Abuse
  National Institute of Environmental Health Sciences
  Application Receipt Date(s): July 14, 2022